Stocks Health care GLUE
NASDAQ · Health careMonte Rosa Therapeutics, Inc. (GLUE)
Monte Rosa Therapeutics, Inc. brought in $28.7M of revenue over the twelve months to June 30, 2026, down 83.9% from a year earlier. It posted a net loss of $161.1M. In fiscal 2025 capital spending exceeded operating cash flow by $27.5M. At June 30, 2026 it held $90.1M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 6, 2026.
What Monte Rosa Therapeutics, Inc. does
Monte Rosa Therapeutics, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker GLUE.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $123.7M | -$38.6M | n/a | -$27.5M |
| 2024 | $75.6M | -$72.7M | n/a | $38M |
| 2023 | $0 | -$135.4M | n/a | -$62.8M |
| 2022 | n/a | -$108.5M | n/a | -$105.4M |
| 2021 | n/a | -$74M | -$2.96 | -$69.1M |
| 2021 | n/a | -$35.9M | -$23.65 | -$26.4M |
Latest SEC filings
What Monte Rosa Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 8, 2026
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026Passive stake (5% or more) SCHEDULE 13G
- August 6, 2026Quarterly report 10-Q · period to June 30, 2026
- August 6, 2026
- July 8, 2026Passive stake changed SCHEDULE 13G/A
- July 6, 2026Activist stake changed SCHEDULE 13D/A
- June 11, 2026
- May 15, 2026Passive stake changed SCHEDULE 13G/A
- May 15, 2026Passive stake changed SCHEDULE 13G/A
Questions about GLUE
What does Monte Rosa Therapeutics, Inc. do?
Monte Rosa Therapeutics, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker GLUE.
Is Monte Rosa Therapeutics, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $161.1M on revenue of $28.7M.
How much revenue does Monte Rosa Therapeutics, Inc. make?
Over the twelve months to June 30, 2026 Monte Rosa Therapeutics, Inc. reported revenue of $28.7M. That is 83.9% less than a year earlier.
When did Monte Rosa Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 6, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the investor disclosure from September 8, 2026.
Similar companies
Follow GLUE
Get an email when Monte Rosa Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow GLUE: get an email when it filesWhere the numbers come from
Financial figures are the values Monte Rosa Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.